<DOC>
	<DOC>NCT00992238</DOC>
	<brief_summary>The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of UrispasÂ® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.</brief_summary>
	<brief_title>A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Flavoxate</mesh_term>
	<criteria>Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening Positive test results for HIV or Hepatitis B or C History of allergy or sensitivity to Flavoxate hydrochloride or related drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>